Esperion Therapeutics | ESPR - Current Liabilities


Esperion Therapeutics reported $300.36M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amarin USD 179.64M 14.82M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
CSL USD 4.61B 207M Dec/2025
Cytokinetics USD 199.18M 3.27M Mar/2026
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Geron USD 73.57M 40.25M Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 2.4B 408M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025